Our aims
The aims of EUPATI CH are to act as the central point for inquiries and cooperation platform for patient empowerment and involvement in medicines R&D processes in Switzerland.
1. Contributing to patient empowerment for active involvement in medicines research and development (R&D).
2. Supporting public awareness raising for the EUPATI education material.
3. Fostering partnerships with medicines R&D stakeholders in Switzerland to promote public involvement in all aspects of medicines R&D.
Donation
EUPATI CH is a nonprofit organisation. In order to fullfill our aims and retain our independence, we need financial support.
EUPATI CH acknowledges any funds and grants. Please do not hesitate to contact us.
E-mail: secretariat@ch.eupati.eu
Bank account details
Swiss postfinance account:
IBAN: CH84 0900 0000 8956 5298 4
BIC: POFICHBEXXX
Statutes
The EUPATI CH statutes are available here
in english (v4_200423)
in german (v4_200423)
in french (v4_200423)
in italian (v4_200423)
Annex 1 (Code of Conduct) and Annex 2 (Advisory Board_v1.3) available in english.
Bodies of EUPATI CH
- The General Assembly of EUPATI CH,
- The Executive Board,
- The Auditors,
- The Advisory Board.
Contact
European Patient’s Academy on Therapeutic Innovation (EUPATI CH)
Switzerland / Schweiz / Suisse / Svizzera
Secretariat
℅ SCTO, Effingerstrasse 35, 3008 Bern, Switzerland
+41 31 307 10 40
secretariat@ch.eupati.eu
Membership
Please send your completed application form for membership to the Executive Board, via its secretariat. By applying for membership (in writing or verbally) you automatically agree with our statutes.
The Executive Board will inform you on its decision on your membership application.
Categories of membership
EUPATI CH has the following membership categories:
- Ordinary members: individual persons,
- Ordinary members: institution representatives
- Supporting members with no voting rights: institutions who wish to financially support without conditions
Application form
You can download the application form here
Membership fees
Membership fees for 2018 were determined by the General Assembly on October 26, 2017, a hardship clause exists for individuals who cannot pay this amount (statutes):
- Individual persons: CHF 30.-
- Institutions / Organisations: at least CHF 50.- (but are most welcome to pay a higher amount)
- Supporting Institutions / Organisations: CHF 2000.-
Newsletter EUPATI CH
Newsletter Issue 09 (28.05.2020)
in english, german, french
Newsletter Issue 08 (16.12.2019)
in english, german
Newsletter Issue 07 (25.06.2019)
in english, german
Newsletter Issue 06 (17.12.2018)
in english, german
Newsletter Issue 05 (07.08.2018)
in english, german
Newsletter Issue 04 (10.05.2018)
in english, german, french, italian
Newsletter Issue 03 (08.12.2017)
in english, german, french, italian
Newsletter Issue 02 (11.09.2017)
in english, german, french, italian
Newsletter Issue 01 (26.05.2017)
in english, german, french, italian
Strategy and Workplan
Strategy and workplan of the EUPATI CH association 2017 - 2020 is available on request at the secretariat.
Support for the implementation of the workplan 2018/2019 is being received by:
- Amgen
- Janssen-Cilag AG
- Pfizer AG
- Roche Pharma (Schweiz) AG
- Takeda Pharma AG
Annual Reports
NEW: Annual Report 2019
in english, german, french, italian
Annual Report 2018
in english, german, french, italian
Annual Report 2016/2017
in english, german, french, italian
Publications and Articles
EUPATI CH articles, statements, interviews and citations.
Clinicum 2019
Computerworld 2019
Farner Blog 2019
Positivrat May 2016
Pharmafakten May 2016
Krebsbulletin December 2016
Pharmajournal April 2017
Lymphoma Info Mai 2017
EUPATI CH Flyers and Postcards
EUPATI CH flyers 2018
in english, german, french, italian
EUPATI CH postcards 2018
Postcards in all languages
Members
Patient representatives and organisations
Positivrat Schweiz
Swiss Forum Lung Cancer
Lymphoma Schweiz
Krebsforschung Schweiz
FMF & AID Global Association
Schweizerische Morbus Crohn / Colitis ulcerosa Vereinigung (SMCC )
Patient Advocate for Cancer Research and Treatment (PACRT)
Verband Nierenpatienten Schweiz (VNPS)
Association Romande du Syndrome de Sjögren
SMA Schweiz
Academic representatives and organisations
University Hospital Basel (USB)
Ente Ospedaliero Cantonale (EOC)
Swiss Clinical Trial Organisation (SCTO)
Gesundheitsbildung Schweiz
Schweizerische Arbeitsgemeinschaft für Klinsche Krebsforschung ( SAKK)
Clinical Trials Center, University Hospital Zürich
Pharmaceutical Industry and for-profit organisations
Janssen-Cilag AG
Bristol-Myers Squibb
Individual members
Matthew May
Dr. Brigitte Franke-Bray
Stéphane Charbon
Emilie Berger
Prof. Uyen Huynh-Do
Dr. Julia Amann
Max Lippuner
Steven Bourke
Debra De Silva-Sun
Vanya Loroch
Judith Safford
Anne-Lise Ducournau Lichtenberg
Lucie Hofmann
Ivo Schauwecker
Larisa Aragon Castro
Ayomi Gunawardhana
Catherine Bates
Rosine Mucklow
Beatrice Heim
Executive Board
President
Ivo Schauwecker (Patient and academic representative)
Vice-President
Hansruedi Völkle (Positivrat Schweiz)
Secretariat
Caecilia Schmid (SCTO)
Communications officer
open for application
Treasurer
open for application
Other board members
Rosmarie Pfau (lymphome.ch, EUPATI Fellow)
Marie Mi Bonde Hansen (USB Basel)
Cristiana Sessa (EOC Ticino)
Annette Magnin (SCTO)
Larisa Aragon (Patient and academic representative)
Stephan Schobinger (Patient and academic representative)
Catherine Bates (Academic representative)
Advisory Board
Our Advisory Board (AB) shall provide non-binding expert advice and guidance and support EUPATI CH strategically, read more about your roles here.
Membership of the Advisory Board (AB) is open to all patients, patient advocates, patient organisations, consumer organisations, academics, institutions, university hospitals, healthcare associations, industry representatives, companies, government agencies representatives, regulatory authorities, medical journalists and anyone interested.
A request to become an Advisory Board member of EUPATI CH shall be sent to the Executive Board by sending an email to the secretariat indicating the intent and commitment to support the platform.